Stockscreener 앱 받기
3.15
2.27%
0.07
시간 외 거래:
3.13
-0.02
-0.63%
전일 마감가:
$3.08
열려 있는:
$3.13
하루 거래량:
3.63M
Relative Volume:
2.86
시가총액:
$461.11M
수익:
$185.74M
순이익/손실:
$-230.76M
주가수익비율:
-3.4772
EPS:
-0.9059
순현금흐름:
$-70.72M
1주 성능:
-13.22%
1개월 성능:
+6.42%
6개월 성능:
+9.00%
1년 성능:
+28.57%
1일 변동 폭
$3.00
$3.17
1주일 범위
$3.00
$3.73
52주 변동 폭
$1.665
$4.105
마라바이 라이프 Stock (MRVI) Company Profile
명칭
Maravai Lifesciences Holdings Inc
전화
(858) 546-0004
주소
10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO
Compare MRVI vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MRVI
Maravai Lifesciences Holdings Inc
|
3.15 | 450.86M | 185.74M | -230.76M | -70.72M | -0.9059 |
|
VRTX
Vertex Pharmaceuticals Inc
|
466.10 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
756.91 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
703.30 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
318.91 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
289.65 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
마라바이 라이프 Stock (MRVI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-26 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-12-19 | 개시 | Guggenheim | Neutral |
| 2024-12-05 | 다운그레이드 | Goldman | Neutral → Sell |
| 2024-11-14 | 개시 | Wolfe Research | Peer Perform |
| 2024-11-08 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2024-08-28 | 개시 | Wells Fargo | Overweight |
| 2024-08-13 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-04-10 | 개시 | Craig Hallum | Buy |
| 2023-12-12 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-08-08 | 다운그레이드 | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2023-05-23 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2023-05-09 | 다운그레이드 | Goldman | Buy → Neutral |
| 2023-01-05 | 다운그레이드 | UBS | Buy → Neutral |
| 2022-12-14 | 개시 | Deutsche Bank | Buy |
| 2022-12-07 | 개시 | RBC Capital Mkts | Outperform |
| 2022-11-03 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-08-25 | 개시 | Credit Suisse | Outperform |
| 2021-08-05 | 재개 | Credit Suisse | Outperform |
| 2020-12-16 | 개시 | KeyBanc Capital Markets | Overweight |
| 2020-12-15 | 개시 | BofA Securities | Buy |
| 2020-12-15 | 개시 | Credit Suisse | Outperform |
| 2020-12-15 | 개시 | Goldman | Buy |
| 2020-12-15 | 개시 | Jefferies | Buy |
| 2020-12-15 | 개시 | Robert W. Baird | Outperform |
| 2020-12-15 | 개시 | Stifel | Buy |
| 2020-12-15 | 개시 | William Blair | Outperform |
| 2020-12-14 | 개시 | UBS | Buy |
모두보기
마라바이 라이프 주식(MRVI)의 최신 뉴스
Maravai LifeSciences (NASDAQ:MRVI) Sees Large Volume IncreaseStill a Buy? - MarketBeat
2026-03-15 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Maravai LifeSciences Holdings, Inc. (MRVI) and Encourages Stockholders to Learn More About the Investigation | NDAQ:MRVI | Press Release - Stockhouse
Bronstein, Gewirtz & Grossman, LLC Encourages Maravai LifeSciences Holdings, Inc. (MRVI) Investors to Inquire about Securities Investigation - ACCESS Newswire
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Given Average Recommendation of “Hold” by Analysts - Defense World
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Given Average Recommendation of "Hold" by Analysts - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Maravai LifeSciences Holdings, Inc. (MRVI) And Encourages Stockholders to Reach Out - ACCESS Newswire
Maravai LifeSciences Holdings Q1 2025 Earnings Preview - MSN
How rising interest rates impact Maravai LifeSciences Holdings Inc. stockEntry Point & Precise Trade Entry Recommendations - Naître et grandir
How does Maravai LifeSciences Holdings Inc score in quality rankings2025 Big Picture & Fast Momentum Entry Tips - baoquankhu1.vn
Targets Report: What are Maravai LifeSciences Holdings Incs earnings expectations2025 Price Targets & Free Fast Gain Swing Trade Alerts - baoquankhu1.vn
Maravai LifeSciences Holdings, Inc. (MRVI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Maravai LifeSciences Sees Unusually High Options Volume (NASDAQ:MRVI) - MarketBeat
Royce & Associates LP Has $5.06 Million Stock Position in Maravai LifeSciences Holdings, Inc. $MRVI - MarketBeat
First Eagle Investment Management LLC Makes New Investment in Maravai LifeSciences Holdings, Inc. $MRVI - MarketBeat
MRVI Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
MRVI Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Maravai Lifesciences Charts Early Turnaround in 2025 - TipRanks
Maravai LifeSciences (NASDAQ:MRVI) Upgraded by Wall Street Zen to "Hold" Rating - MarketBeat
Maravai LifeSciences Holdings (MRVI) Stock Analysis: Assessing a Potential 14% Upside in the Biotechnology Sector - DirectorsTalk Interviews
Maravai LifeSciences Holdings (MRVI) Posts US$130.8m TTM Loss Challenging Margin Recovery Narratives - simplywall.st
Maravai LifeSciences (NASDAQ:MRVI) Shares Gap UpStill a Buy? - MarketBeat
Is Maravai LifeSciences Holdings Inc.’s ROE strong enoughMarket Growth Report & Fast Exit and Entry Trade Guides - mfd.ru
Maravai Q4 2025 slides: return to positive EBITDA on cost cuts - Investing.com Nigeria
Maravai LifeSciences Holdings, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Maravai LifeSciences Holdings Inc (MRVI) Q4 2025 Earnings Call Highlights: Surpassing Revenue ... By GuruFocus - Investing.com Canada
Maravai Lifesciences Reports Fourth Quarter and Full Year 2025 Financial Results - BioSpace
Maravai LifeSciences Q4 Earnings Call Highlights - MarketBeat
Maravai LifeSciences Holdings, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:MRVI) 2026-02-26 - Seeking Alpha
Maravai LifeSciences Holdings Inc (MRVI) Q4 2025 Earnings Call H - GuruFocus
Maravai LifeSciences Holdings, Inc. (MRVI) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance
Maravai Q4 2025 slides: return to positive EBITDA on cost cuts By Investing.com - Investing.com South Africa
Earnings call transcript: Maravai Lifesciences Q4 2025 beats EPS forecast, stock jumps 4.5% - Investing.com Canada
MRVI: 2025 saw revenue beat, margin recovery, and strong 2026 growth and profitability guidance - TradingView
Maravai LifeSciences Holdings Inc reports results for the quarter ended September 30Earnings Summary - TradingView
Maravai LifeSciences (NASDAQ:MRVI) Issues Earnings Results, Beats Expectations By $0.03 EPS - MarketBeat
Maravai LifeSciences Holdings, Inc. Provides Earnings Guidance for the Full Year 2026 - marketscreener.com
MRVI Projects FY26 Adjusted EBITDA Between $18M and $20M - GuruFocus
Maravai LifeSciences (MRVI) Surpasses Revenue Expectations in Q4 - GuruFocus
Maravai LifeSciences (NASDAQ: MRVI) posts 2025 loss but targets 2026 EBITDA rebound - Stock Titan
Maravai LifeSciences Q4 2025 Earnings Call Transcript - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages Maravai LifeSciences Holdings, Inc. (MRVI) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Maravai LifeSciences Holdings, Inc. (MRVI) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
What are Maravai LifeSciences Holdings Inc.’s growth levers2025 Geopolitical Influence & Weekly High Return Stock Opportunities - mfd.ru
Maravai LifeSciences Holdings, Inc. $MRVI Shares Bought by Monaco Asset Management SAM - MarketBeat
Value Recap: What is the PEG ratio of Maravai LifeSciences Holdings IncEarnings Overview Report & Daily Entry Point Alerts - baoquankhu1.vn
Maravai LifeSciences Holdings (MRVI) Investor Outlook: Navigating a 27.55% Upside Amidst Challenging Metrics - DirectorsTalk Interviews
Maravai LifeSciences Holdings, Inc. (MRVI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Stock Traders Purchase High Volume of Maravai LifeSciences Put Options (NASDAQ:MRVI) - MarketBeat
Maravai LifeSciences (MRVI) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
12 West Capital (NASDAQ: MRVI) discloses 6.2% beneficial stake in Maravai - Stock Titan
Is There An Opportunity With Maravai LifeSciences Holdings, Inc.'s (NASDAQ:MRVI) 34% Undervaluation? - Yahoo Finance
마라바이 라이프 (MRVI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.99%
0.71%
자본화:
|
볼륨(24시간):